NEWS out. http://ir.stockpr.com/amarantus/compa
Post# of 30028
Posted On: 09/10/2014 1:04:41 PM
NEWS out.
http://ir.stockpr.com/amarantus/company-news/...rence-2014
Amarantus to Present Orphan Ocular Data at Targeting Ocular Disorders Conference 2014
SAN FRANCISCO and GENEVA, Sept. 10, 2014 (GLOBE NEWSWIRE)
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced that Dr. Roman Urfer, Chief Development Officer at NeuroAssets Sarl, will be presenting efficacy data for MANF in an undisclosed orphan ocular indication at Targeting Ocular Disorders 2014. NeuroAssets is a Swiss-based neuroscience-focused consulting firm engaged by Amarantus to support the translational development of MANF. Dr. Urfer's presentation will be made at 3:40pm ET on October 6th, 2014 at the Westin Boston Waterfront Market in Boston, MA.
http://ir.stockpr.com/amarantus/company-news/...rence-2014
Amarantus to Present Orphan Ocular Data at Targeting Ocular Disorders Conference 2014
SAN FRANCISCO and GENEVA, Sept. 10, 2014 (GLOBE NEWSWIRE)
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced that Dr. Roman Urfer, Chief Development Officer at NeuroAssets Sarl, will be presenting efficacy data for MANF in an undisclosed orphan ocular indication at Targeting Ocular Disorders 2014. NeuroAssets is a Swiss-based neuroscience-focused consulting firm engaged by Amarantus to support the translational development of MANF. Dr. Urfer's presentation will be made at 3:40pm ET on October 6th, 2014 at the Westin Boston Waterfront Market in Boston, MA.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼